42 results
Page 2 of 3
8-K
EX-99.1
z7tgqrmd9pdobvk1
12 Aug 21
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
4:19pm
8-K
EX-99.1
y2jyh2dt4c6eb6
14 Jul 21
Entry into a Material Definitive Agreement
7:07am
8-K
EX-99.1
3r29usz5
13 May 21
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
4:18pm
8-K
EX-99.1
qx53dw0e4ak133p8
6 May 21
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
4:24pm
8-K
0lmjd6rb5s59v7jpmd
6 May 21
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
4:24pm
8-K
EX-99.1
7m1 3j8vw44
28 Apr 21
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
8:07am
10-K
7rkoggfmgc2joibxael
25 Mar 21
Annual report
12:00am
8-K
EX-99.2
ikuwkb6n 1bhphw2
12 Nov 20
Nkarta Reports Third Quarter 2020 Financial Results
4:08pm
10-Q
qlcpmp1jg37 9qbf
20 Aug 20
Quarterly report
4:51pm
8-K
EX-99.1
2ylaxly4cq9e
14 Jul 20
Amendments to Articles of Incorporation or Bylaws
4:10pm
424B4
0zdxr0igels
10 Jul 20
Prospectus supplement with pricing info
9:35pm
S-1/A
yufwuw
2 Jul 20
IPO registration (amended)
5:17pm
S-1
z3xtoj5 sgyemh6ck9h
19 Jun 20
IPO registration
3:24pm
DRS/A
dgalc rktj72y3f
19 May 20
Draft registration statement (amended)
12:00am